Ziftomenib Maintenance Post Allo-HCT
NCT06440135
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
22
Enrollment
OTHER
Sponsor class
Conditions
Acute Myeloid Leukemia
Acute Myeloid Leukemia in Remission
NPM1 Mutation
KMT2A Rearrangement
Interventions
DRUG:
Ziftomenib
Sponsor
Massachusetts General Hospital